{"id":13591,"date":"2020-06-22T09:00:00","date_gmt":"2020-06-22T07:00:00","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=13591"},"modified":"2026-03-03T10:00:53","modified_gmt":"2026-03-03T09:00:53","slug":"three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/","title":{"rendered":"Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada &#038; Partner Markets, Biogen"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg\" alt=\"\" class=\"wp-image-7154\"\/><\/figure>\n\n\n\n<p><strong>Since\nits founding in 1978, Biogen\u2019s goal has been to defeat devastating neurological\ndiseases. What has been achieved since then?<\/strong><\/p>\n\n\n\n<p>We have made\ngreat progress, but there is still so far to go. &nbsp;For more than 40 years,\nBiogen has been tackling some of the most complex and challenging conditions:\nMultiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Alzheimer\u2019s disease and\nmore. &nbsp;As pioneers in neuroscience, we have developed and delivered life-changing\nmedicines for diseases that were previously untreatable. We have helped\nhundreds of thousands of people live fuller, better lives. But this is only the\nbeginning. We continue to take risks to pursue innovation in areas of high\nunmet medical need. Even when we face setbacks, we refuse to give up. We learn\nfrom experience for a deeper understanding of disease and how we might treat\nit. That spirit, inspired by our visionary founders, drives us forward in\neverything we do.<\/p>\n\n\n\n<p><strong>Biogen\nis a member of Interpharma since 2013, you have been member of the board since\n2016. What is your motivation to be an active part of the association of\nresearch-based pharmaceutical companies in Switzerland?<\/strong><\/p>\n\n\n\n<p>Biogen was\nfounded in Geneva: in fact, that\u2019s what the \u201cgen\u201d in our name stands for.\nToday, we manage our international operations from our headquarters in Baar. We\ncurrently have about 800 employees in Switzerland and invest about CHF 1.5\nbillion in our next-generation biologics manufacturing facility in Luterbach\nnear Solothurn. So&nbsp;Switzerland\nis a very important part of our past, present and future. Being part of\nInterpharma, we have the opportunity to work with other leading firms to help\nshape an efficient, high-quality healthcare system that provides patients with\nrapid access to the innovative treatments they need. As members of Interpharma,\nwe can help more people get access to the best possible care &#8211; both here in\nSwitzerland and worldwide.<\/p>\n\n\n\n<p><strong>With\nCovid-19 the world is experiencing an unprecedented health crisis. What\nmeasures does Biogen take to help patients and communities?<\/strong><\/p>\n\n\n\n<p>We put patients first in everything we do,\nincluding our response to COVID-19. We have committed more than $10 million\nfrom the Biogen Foundation to organisations fighting COVID-19 around the world,\nincluding Switzerland. Our donations are focused on expanding testing options,\neasing the strain on medical systems, providing training for frontline health\nworkers, and supporting access to necessities like food.&nbsp;<\/p>\n\n\n\n<p>We are also part of scientific efforts to\ndevelop treatments or vaccines.&nbsp;We entered into a Clinical Development and\nManufacturing agreement with Vir Biotechnology, Inc for the process development\nand clinical manufacturing of human monoclonal antibodies for the potential\ntreatment of COVID-19.&nbsp;In collaboration with the Broad Institute of MIT\nand Harvard and Partners HealthCare we have also launched a consortium to build\nand share a new, first-of-its-kind biobank. At the biobank, Biogen employees\nand their family members who have previously tested positive for coronavirus\nand recovered from COVID-19 can volunteer to donate blood samples, provide\nmedical data and other information about their symptoms. &nbsp;<\/p>\n\n\n\n<p>These are just a few of the things we are\ndoing, and we will continue to look for more ways to help. &nbsp;Working\ntogether, the scientific community, public health authorities and the\npharmaceutical industry will rise to this challenge.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Since its founding in 1978, Biogen\u2019s goal has been to defeat devastating neurological diseases. What has been achieved since then? We have made great progress, but there is still so far to go. &nbsp;For more than 40 years, Biogen has been tackling some of the most complex and challenging conditions: Multiple Sclerosis (MS), Spinal Muscular [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1721,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[112,129],"class_list":["post-13591","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-covid-19-en","tag-pharmastandort-2030-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada &amp; Partner Markets, Biogen - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada &amp; Partner Markets, Biogen\" \/>\n<meta property=\"og:description\" content=\"Since its founding in 1978, Biogen\u2019s goal has been to defeat devastating neurological diseases. What has been achieved since then? We have made great progress, but there is still so far to go. &nbsp;For more than 40 years, Biogen has been tackling some of the most complex and challenging conditions: Multiple Sclerosis (MS), Spinal Muscular [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-22T07:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T09:00:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1965\" \/>\n\t<meta property=\"og:image:height\" content=\"2076\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada &#038; Partner Markets, Biogen\",\"datePublished\":\"2020-06-22T07:00:00+00:00\",\"dateModified\":\"2026-03-03T09:00:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/\"},\"wordCount\":545,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg\",\"keywords\":[\"Covid-19\",\"Pharmastandort 2030\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2020\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/\",\"url\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/\",\"name\":\"Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada & Partner Markets, Biogen - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg\",\"datePublished\":\"2020-06-22T07:00:00+00:00\",\"dateModified\":\"2026-03-03T09:00:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg\",\"width\":1965,\"height\":2076},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada &#038; Partner Markets, Biogen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada & Partner Markets, Biogen - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/","og_locale":"en_US","og_type":"article","og_title":"Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada & Partner Markets, Biogen","og_description":"Since its founding in 1978, Biogen\u2019s goal has been to defeat devastating neurological diseases. What has been achieved since then? We have made great progress, but there is still so far to go. &nbsp;For more than 40 years, Biogen has been tackling some of the most complex and challenging conditions: Multiple Sclerosis (MS), Spinal Muscular [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/","og_site_name":"Interpharma","article_published_time":"2020-06-22T07:00:00+00:00","article_modified_time":"2026-03-03T09:00:53+00:00","og_image":[{"width":1965,"height":2076,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg","type":"image\/jpeg"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"Written by":"berta_admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada &#038; Partner Markets, Biogen","datePublished":"2020-06-22T07:00:00+00:00","dateModified":"2026-03-03T09:00:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/"},"wordCount":545,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg","keywords":["Covid-19","Pharmastandort 2030"],"inLanguage":"en-US","copyrightYear":"2020","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/","url":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/","name":"Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada & Partner Markets, Biogen - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg","datePublished":"2020-06-22T07:00:00+00:00","dateModified":"2026-03-03T09:00:53+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/06\/Johanna-Naderer.jpg","width":1965,"height":2076},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/en\/blog\/three-questions-to-johanna-friedl-naderer-president-europe-canada-partner-markets-biogen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/en\/"},{"@type":"ListItem","position":2,"name":"Three questions to Johanna Friedl-Naderer \u2013 President Europe, Canada &#038; Partner Markets, Biogen"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/posts\/13591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/comments?post=13591"}],"version-history":[{"count":1,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/posts\/13591\/revisions"}],"predecessor-version":[{"id":13592,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/posts\/13591\/revisions\/13592"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/media\/1721"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/media?parent=13591"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/tags?post=13591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}